RX-21101

RX-21101 is a polymer-conjugated form of docetaxel designed for targeted cancer treatment. It utilizes a folate-targeting moiety to direct docetaxel into tumor cells, aiming to maximize efficacy and minimize toxicity compared to conventional intravenous docetaxel therapy. The mechanism leverages the enhanced permeability and retention effect of tumors and folate receptor targeting to increase docetaxel delivery to cancer cells while reducing exposure to normal tissues. In preclinical studies, RX-21101 showed improved efficacy and reduced adverse events such as anemia, infection, fever, and neuropathy, which are common with standard docetaxel therapy. RX-21101 is in preclinical development for neoplasms including breast, ovarian, prostate, and non-small cell lung cancers[1][3][7][9].

Brand names

RX-21101RX21101RX 21101

Other names

N-(2-Hydroxypropyl) methacrylamide-docetaxel-folateHPMA-docetaxel-folate